| アブストラクト | BACKGROUND: Interleukin-6 (IL-6) monoclonal antibodies are commonly acknowledged for their efficacy in managing coronavirus disease 2019 (COVID-19); however, there remains a paucity of comprehensive studies on their potential adverse effects. RESEARCH DESIGN AND METHODS: This is a retrospective pharmacovigilance investigation. We employed FAERS using OpenVigil FDA to detect adverse reactions linked to the interleukin-6 antagonist tocilizumab and sarilumab. RESULTS: Completely 17,037,364 reports were collected from the FAERS database, with 67,976 reports identified as 'primary suspected (PS)' adverse events (AEs) for tocilizumab, and 12,560 reports for sarilumab. AEs induced by both drugs involved 27 organ systems. 109 significant disproportionality preferred terms (PTs) of tocilizumab and 158 significant disproportionality PTs meeting the criteria of sarilumab across all four algorithms were retained simultaneously. A higher incidence of adverse reactions occurred in females aged 45-64 years, with a higher rate of subsequent hospitalization. Both drugs exhibited adverse reactions consistent with previously reported side effects, such as leukopenia, elevated liver enzymes, and hypercholesterolemia. Additionally, there was a strong correlation with gastrointestinal issues. Unexpected significant adverse events, including diabetes, fluctuations in blood pressure, drug ineffectiveness, malignancies, and disorders of the nervous system, were also observed. Gender and age differences existed in AEs signals related to IL-6RAs. CONCLUSION: Our study identified significant new AE signals for interleukin-6 receptor antagonists, potentially supporting clinical monitoring and risk identification for this class of drugs. |
|---|
| ジャーナル名 | Expert opinion on drug safety |
|---|
| 投稿日 | 2024/7/26 |
|---|
| 投稿者 | Hu, Jing; Sun, Yao; Zuo, Xiangrong; Zou, Ying |
|---|
| 組織名 | Department of Pharmacy, The First Affiliated Hospital of Nanjing Medical;University, Nanjing, Jiangsu, People's Republic of China.;Department of Pharmacy, Children's Hospital of Nanjing Medical University,;Nanjing, Jiangsu, People's Republic of China.;Department of Critical Care Medicine, The First Affiliated Hospital of Nanjing;Medical University, Nanjing, Jiangsu, People's Republic of China. |
|---|
| Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/39049740/ |
|---|
